Gufic BioScience

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE742B01025
  • NSEID: GUFICBIO
  • BSEID: 509079
INR
355.40
-2.75 (-0.77%)
BSENSE

Dec 05

BSE+NSE Vol: 34.09 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationHalf Yearly Results
Results Snapshot
Figures in Cr
Consolidate Half Yearly Results
Sep'25
Sep'24
Sep'23
Net Sales
460.78
406.99
409.89
Other Operating Income
0.00
0.00
0.00
Total Operating income
460.78
406.99
409.89
Raw Material Cost
201.99
147.70
175.67
Purchase of Finished goods
39.95
29.02
31.72
(Increase) / Decrease In Stocks
-36.73
14.15
-1.45
Employee Cost
73.45
57.52
50.15
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
110.97
84.21
78.62
Total Expenditure (Excl Depreciation)
389.63
332.60
334.71
Operating Profit (PBDIT) excl Other Income
71.15
74.39
75.18
Other Income
3.04
1.37
0.87
Operating Profit (PBDIT)
74.19
75.76
76.05
Interest
18.82
9.80
8.53
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
55.37
65.96
67.52
Depreciation
15.49
8.60
8.53
Profit Before Tax
39.88
57.36
58.99
Tax
9.99
14.73
15.16
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
29.89
42.62
43.83
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
29.89
42.62
43.83
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
29.89
42.62
43.83
Equity Capital
10.03
10.03
9.69
Face Value
1.0
1.0
1.0
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
2.98
4.25
4.52
Diluted Earnings per share
2.98
4.25
4.52
Operating Profit Margin (Excl OI)
15.44%
18.28%
18.34%
Gross Profit Margin
12.02%
16.21%
16.47%
PAT Margin
6.49%
10.47%
10.69%
Public Share Holdings (%)
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
Half Yearly Analysis Highlights
stock-summary

Net Sales

Growth in half year ended Sep 2025 is 13.22% vs -0.71% in Sep 2024

stock-summary

Consolidate Net Profit

Growth in half year ended Sep 2025 is -29.87% vs -2.76% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

Growth in half year ended Sep 2025 is -4.36% vs -1.05% in Sep 2024

stock-summary

Interest

Growth in half year ended Sep 2025 is 92.04% vs 14.89% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

Growth in half year ended Sep 2025 has fallen from Sep 2024

Compare Half Yearly Results Of Gufic BioScience With
Markets Mojo
Figures in Cr
Consolidate Half Yearly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
460.78
299.75
161.03
53.72%
Other Operating Income
0.00
0.00
0.00
Total Operating income
460.78
299.75
161.03
53.72%
Raw Material Cost
201.99
75.46
126.53
167.68%
Purchase of Finished goods
39.95
38.55
1.40
3.63%
(Increase) / Decrease In Stocks
-36.73
4.42
-41.15
-931.00%
Employee Cost
73.45
51.28
22.17
43.23%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
110.97
46.36
64.61
139.37%
Total Expenditure (Excl Depreciation)
389.63
216.07
173.56
80.33%
Operating Profit (PBDIT) excl Other Income
71.15
83.68
-12.53
-14.97%
Other Income
3.04
8.76
-5.72
-65.30%
Operating Profit (PBDIT)
74.19
92.44
-18.25
-19.74%
Interest
18.82
11.24
7.58
67.44%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
55.37
81.20
-25.83
-31.81%
Depreciation
15.49
14.09
1.40
9.94%
Profit Before Tax
39.88
67.11
-27.23
-40.58%
Tax
9.99
15.82
-5.83
-36.85%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
29.89
51.29
-21.40
-41.72%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
29.89
51.29
-21.40
-41.72%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.00
0.82
-0.82
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
29.89
52.11
-22.22
-42.64%
Equity Capital
10.03
46.05
-36.02
-78.22%
Face Value
1.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
2.98
11.32
-8.34
-73.67%
Diluted Earnings per share
2.98
11.14
-8.16
-73.25%
Operating Profit Margin (Excl OI)
15.44%
30.50%
0.00
-15.06%
Gross Profit Margin
12.02%
29.59%
0.00
-17.57%
PAT Margin
6.49%
18.69%
0.00
-12.20%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 460.78 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 13.22% vs -0.71% in Sep 2024

Half Yearly - Consolidate Net Profit
Consolidate Net Profit 29.89 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -29.87% vs -2.76% in Sep 2024

Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 71.15 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -4.36% vs -1.05% in Sep 2024

Half Yearly - Interest
Interest 18.82 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 92.04% vs 14.89% in Sep 2024

Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 15.44%
in Sep 2025

Figures in %
stock-summary

Growth in half year ended Sep 2025 has fallen from Sep 2024